CN1289100C - 一种具有延缓衰老、免疫调节功能的胶囊及其制备方法 - Google Patents
一种具有延缓衰老、免疫调节功能的胶囊及其制备方法 Download PDFInfo
- Publication number
- CN1289100C CN1289100C CN 03141626 CN03141626A CN1289100C CN 1289100 C CN1289100 C CN 1289100C CN 03141626 CN03141626 CN 03141626 CN 03141626 A CN03141626 A CN 03141626A CN 1289100 C CN1289100 C CN 1289100C
- Authority
- CN
- China
- Prior art keywords
- capsule
- group
- dosage
- present
- radix panacis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 57
- 230000006870 function Effects 0.000 title abstract description 13
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 230000001105 regulatory effect Effects 0.000 title abstract 2
- 210000000987 immune system Anatomy 0.000 title 1
- 239000000843 powder Substances 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 241000894006 Bacteria Species 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 230000032683 aging Effects 0.000 claims description 9
- 230000002519 immonomodulatory effect Effects 0.000 claims description 6
- 238000005516 engineering process Methods 0.000 claims description 4
- 230000005251 gamma ray Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 240000005373 Panax quinquefolius Species 0.000 abstract 2
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract 2
- 230000036039 immunity Effects 0.000 abstract 2
- 230000009758 senescence Effects 0.000 abstract 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 45
- 238000012360 testing method Methods 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 20
- 230000037396 body weight Effects 0.000 description 20
- 238000000034 method Methods 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 241000700159 Rattus Species 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000000242 pagocytic effect Effects 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 235000013305 food Nutrition 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 6
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 230000036737 immune function Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 208000032170 Congenital Abnormalities Diseases 0.000 description 5
- 206010061619 Deformity Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 4
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- 210000003484 anatomy Anatomy 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 241000190633 Cordyceps Species 0.000 description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000007674 genetic toxicity Effects 0.000 description 3
- 231100000025 genetic toxicology Toxicity 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000288673 Chiroptera Species 0.000 description 2
- 241000255601 Drosophila melanogaster Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 150000003071 polychlorinated biphenyls Chemical class 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000021595 spermatogenesis Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- -1 uracil nucleoside Chemical class 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- NFZYDZXHKFHPGA-UHFFFAOYSA-N 17alpha-hydroxygofruside Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(C(O)=O)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NFZYDZXHKFHPGA-UHFFFAOYSA-N 0.000 description 1
- VCNKUCWWHVTTBY-UHFFFAOYSA-N 18alpha-Oleanane Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4CCC3C21C VCNKUCWWHVTTBY-UHFFFAOYSA-N 0.000 description 1
- OUGUAJZGGCBKHO-UHFFFAOYSA-N 3-O-rutinoside,20-O-beta-D-Glycopyranoside Dammar-24-ene-3,12,20-triol Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC2C(C3C(C4C(C5(CCC(C5C(O)C4)C(C)(CCC=C(C)C)OC4C(C(O)C(O)C(CO)O4)O)C)(C)CC3)(C)CC2)(C)C)O1 OUGUAJZGGCBKHO-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- NTYAVUNEPXGZQJ-LUSMHSHMSA-N CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4O[C@H](COC(=O)CC(O)=O)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C Chemical compound CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4O[C@H](COC(=O)CC(O)=O)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C NTYAVUNEPXGZQJ-LUSMHSHMSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- QXQFFGOMXYKNBA-UHFFFAOYSA-N Chikusetsusaponin V Natural products CC1(C)CCC2(CCC3C(=CCC4C3(C)CCC5C(C)(C)C(CCC45C)OC6OC(C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(=O)O)C2C1)C(=O)OC8OC(CO)C(O)C(O)C8O QXQFFGOMXYKNBA-UHFFFAOYSA-N 0.000 description 1
- NFZYDZXHKFHPGA-QQHDHSITSA-N Chikusetsusaponin-V Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NFZYDZXHKFHPGA-QQHDHSITSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000660877 Coridius Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Natural products O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- RBRANZURTULKJD-UHFFFAOYSA-N ginsenoside Ro Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(C)(C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(=O)O)C(C)(C)C5CCC34C)C2C1)C(=O)OC8OC(CO)C(O)C(O)C8O RBRANZURTULKJD-UHFFFAOYSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- SIOMFBXUIJKTMF-UHFFFAOYSA-N hypoglauterpenic acid Natural products C1CC(O)C(C)(C)C2=CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C SIOMFBXUIJKTMF-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000011430 maximum method Methods 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- BPAWXSVOAOLSRP-UHFFFAOYSA-N oleanane Natural products CCCCCCCCCCCCCCCC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5CC(C)(C)CCC5(C)C(O)CC34C)C1(C)C BPAWXSVOAOLSRP-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- SHCBCKBYTHZQGZ-CJPZEJHVSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-CJPZEJHVSA-N 0.000 description 1
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 206010061393 typhus Diseases 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
动物品种 | 性别 | 数量 | 途径 | 剂量(g/kgBW) | 死亡数 | LD50(g/kgBW) | 结论 |
小鼠 | 雄 | 10 | 经口 | 20 | 0 | >20 | 无毒 |
雌 | 10 | 经口 | 20 | 0 | >20 | 无毒 |
剂量(mg/皿) | TA97 | TA98 | TA100 | TA102 | |||||
-S9 | +S9 | -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | ||
受试物 | 10.05.02.51.00.5 | 94±4125±893±5107±19116±12151±22 | 105±8116±1284±1397±392±3142±25 | 27±427±229±428±327±331±4 | 26±130±628±128±425±327±7 | 170±44220±26224±16172±44201±26190±4 | 185±53183±37127±15168±29187±65141±15 | 281±24266±32265±37285±71278±10285±68 | 278±15311±32227±12263±34274±49242±38 |
自发回变 | |||||||||
阳性对照物 | 剂量(ug/皿) | TA97 | TA98 | TA100 | TA102 | ||||
-S9 | +S9 | -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | ||
SA2-AF2.7-AFMMS9A | 1.010.0100.04.050.0 | 823±22 | 803±49 | 775±80 | 718±25 | 908±42 | 855±50 | 1009±25 | 1020±70 |
剂量(mg/皿) | TA97 | TA98 | TA100 | TA102 | |||||
-S9 | +S9 | -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | ||
受试物 | 10.05.02.51.00.5 | 124±8145±19170±48160±33142±14121±5 | 151±43156±41128±13128±17161±31130±57 | 36±535±537±436±440±136±4 | 29±230±333±135±432±234±9 | 151±21150±34135±25152±26156±21145±11 | 141±3163±21144±20154±5162±21147±32 | 265±19263±3308±58289±22293±36320±19 | 254±18308±13299±2308±12294±14287±34 |
自发回变 | |||||||||
阳性对照物 | 剂量(μg/皿) | TA97 | TA98 | TA100 | TA102 | ||||
-S9 | +S9 | -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | ||
SA2-AF2,7-AFMMS9A | 1.010.0100.04.050.0 | 856±66 | 936±96 | 723±96 | 861±115 | 952±89 | 1035±100 | 1170±77 | 1090±83 |
性别 | 剂量(g/kgBW) | 动物数(只) | 检查细胞数(个) | 微核数(个) | 微核率(‰) |
雄 | 10.005.002.500.00 | 5555 | 5000500050005000 | 7666 | 1.41.21.21.2 |
40mg/kgBW(CP) | 5 | 5000 | 118 | 23.6* | |
雌 | 10.005.002.500.00 | 5555 | 5000500050005000 | 6566 | 1.21.01.21.2 |
40mg/kgBW(CP) | 5 | 5000 | 117 | 23.4* |
剂量(g/kg.bw) | 动物数(只) | 受检***数(个) | ***畸形数(个) | ***畸形率(%) |
5.002.501.250 | 5555 | 5000500050005000 | 911038492 | 1.822.061.681.84 |
40mg/kgBW(CP) | 5 | 5000 | 480 | 9.60 |
性别 | 剂量(g/kgBW) | 动物数(只) | 始重(g) | 第1周(g) | 第2周(g) | 第3周(g) | 第4周 | |
(g)0 | P值 | |||||||
雄 | 3.501.750.870 | 10101010 | 56.32±9.2056.64±8.3656.14±8.4656.98±8.89 | 95.5±13.1696.2±8.2195.9±11.3293.8±12.09 | 143.6±16.89146.5±12.10141.6±15.25139.4±16.97 | 206.7±19.21209.2±16.07211.4±17.96205.2±21.39 | 260.4±25.65263.1±19.19264.7±18.43261.4±27.2 | >0.05>0.05>0.05- |
雌 | 3.501.750.870 | 10101010 | 58.45±8.1858.64±8.2858.81±8.3458.59±7.73 | 90.8±8.9190.9±8.0795.2±9.7094.7±9.53 | 127.0±11.62120.8±11.24131.0±10.56121.6±9.34 | 133.9±13.57148.6±14.01149.3±10.92140.4±5.31 | 195.6±14.56194.6±13.35202.2±14.1194.0±10.94 | >0.05>0.05>0.05- |
性别 | 剂量(g/kgBW) | 动物数(只) | 体重增重(g) | 进食量(g) | 食物利用率 | |
(%) | P值 | |||||
雄 | 3.501.750.870 | 10101010 | 204.08±21206.46±26208.50±28204.42±20 | 668.18±36664.28±40674.62±41646.86±49 | 30.8±2.832.7±3.331.9±3.631.1±2.9 | P>0.05P>0.05P>0.05- |
雌 | 3.501.750.870 | 10101010 | 137.15±17135.96±19143.39±15135.41±16 | 542.51±37527.17±40553.13±37541.46±35 | 25.28±2.725.41±3.025.01±2.924.34±2.8 | P>0.05P>0.05P>0.05- |
性别 | 剂量(g/kgBW) | 动物数(只) | 白细胞计数(×109/L) | 红细胞计数(×1012/L) | 血红蛋白(g/L) |
雄 | 3.501.750.870 | 10101010 | 20.65±3.1520.15±2.9421.02±4.0420.97±4.60 | 6.66±0.426.77±0.406.65±0.466.82±0.42 | 142.0±3.85144.6±5.10143.4±6.8144.0±3.85 |
雌 | 3.501.750.870 | 10101010 | 18.08±2.6118.96±3.2619.19±3.5617.43±3.01 | 6.96±0.316.74±0.266.81±0.316.69±0.46 | 143.1±5.52138.4±5.91142.2±5.75139.9±4.7 |
性别 | 剂量(g/kgBW) | 动物数(只) | 淋巴细胞(%) | 单核与嗜酸细胞(%) | 中性细胞(%) |
雄 | 3.501.750.870 | 10101010 | 77.3±3.2476.3±2.1379.4±2.9478.9±4.13 | 8.32±2.9110.37±1.658.05±2.578.25±3.19 | 14.38±1.9913.36±1.7413.2±1.9212.84±2.75 |
雌 | 3.501.750.870 | 10101010 | 80.98±5.0179.12±3.6680.30±5.1280.37±3.24 | 6.41±1.547.53±1.558.23±4.346.05±2.12 | 12.61±3.7813.35±1.4412.30±3.0213.57±3.27 |
性别 | 剂量g/kgBW | 动物数(只) | 谷丙转氨酶(U/L) | 谷草转氨酶(U/L) | 尿素氮(mmol/L) | 肌酐(umol/L) |
雄 | 3.501.750.870 | 10101010 | 30.2±4.238.1±4.338.2±3.630.0±4.3 | 112.4±9.34114.5±8.60112.8±13.9113.1±11.3 | 5.97±0.65.92±0.75.84±0.65.77±0.7 | 43.7±3.444.2±2.943.2±2.945.9±2.9 |
雌 | 3.501.750.870 | 10101010 | 31.1±5.639.3±5.138.8±5.339.2±3.2 | 116.2±15.7107.8±15.0106.4±14.7118.7±13.9 | 5.91±0.85.82±1.05.81±1.15.84±0.7 | 44.5±2.542.9±2.642.7±2.443.7±3.0 |
性别 | 剂量(g/kgBW) | 动物数(只) | 胆固醇(mmol/L) | 甘油三脂(mmol/L) | 血糖(mmol/L) | 总蛋白(g/L) | 白蛋白g/L) |
雄 | 3.501.750.870 | 10101010 | 1.57±0.181.60±0.261.56±0.131.62±0.21 | 1.33±0.241.28±0.431.23±0.261.46±0.3 | 8.35±0.918.46±0.468.56±0.658.56±0.99 | 51.35±4.753.83±4.651.99±3.054.43±5.1 | 29.6±1.630.5±2.630.1±0.730.8±1.9 |
雌 | 3.501.750.870 | 10101010 | 1.48±0.221.48±0.211.53±0.131.54±0.21 | 1.35±0.431.43±0.231.30±0.361.34±0.43 | 8.91±0.688.48±0.598.82±0.598.95±0.42 | 50.68±1.850.04±3.950.31±3.453.62±4.6 | 28.45±1.328.22±1.328.36±1.429.55±1.4 |
性别 | 剂量(g/kgBW) | 动物数(只) | 肝/体% | 脾/体% | 肾/体% | 睾丸(卵巢)/体% |
雄 | 3.501.750.870 | 10101010 | 4.38±0.974.05±1.324.08±1.434.53±0.60 | 0.33±0.040.38±0.070.36±0.040.37±0.06 | 1.07±0.151.01±0.090.91±0.211.01±0.14 | 1.15±0.141.10±0.091.09±0.091.07±0.14 |
雌 | 3.501.750.870 | 10101010 | 4.52±0.494.44±0.554.87±1.284.81±0.55 | 0.27±0.050.25±0.030.28±0.080.25±0.02 | 1.08±0.101.09±0.151.06±0.0771.01±0.12 | 0.07±0.0090.07±0.0110.07±0.0100.06±0.008 |
组份 | 玉米粉(g) | 蔗糖(g) | 琼脂(g) | 丙酸(ml) | 干酵母粉(g) | 水(ml) |
用量 | 85 | 65 | 7.5 | 5 | 7.5 | 1000 |
试物浓度(%) | 样本数(只) | 平均体重(ug) | 半数死亡时间(天) | 平均寿命(天) | 平均最高寿命(天)a | |||||
雄 | 雌 | 雄 | 雌 | 雄 | 雌 | 雄 | 雌 | 雄 | 雌 | |
0.00.0080.0230.070.21 | 200200200209203 | 217223200216201 | 818825834789796 | 99810129969971008 | 4548494950 | 4646505452 | 46.5±9.847.2±9.548.2±8.350.6±11.6*51.1±10.0* | 49.1±15.049.7±15.553.2±15.8*55.5±14.4*54.6±14.4* | 64.3±5.664.5±4.963.3±2.976.6±8.4*74.6±7.7* | 81.7±3.182.5±5.681.4±4.382.6±2.580.9±4.2 |
组别 | 剂量(g/kg.bw) | 动物数(只) | 初重g | 终重g |
老龄对照低剂量组中剂量组高剂量组 | 0.00.350.701.05 | 10101010 | 56.4±8.955.0±8.152.9±6.453.0±7.2 | 55.9±8.354.9±7.154.4±5.255.1±6.8 |
组别 | 剂量(g/kg.bw) | 动物数(只) | SOD(NU/ml) | LPO(nmol.MDA/ml) | |
1%肝匀浆 | 血清 | 10%肝匀浆 | |||
老龄对照低剂量组中剂量组高剂量组少龄对照 | 0.00.350.701.050.0 | 1010101010 | 370.3±32.8429.8±35.4*412.2±39.7*406.9±23.6*442.7±28.2* | 302.5±52.4302.5±18.7306.3±28.9290.3±38.3360.4±26.9* | 22.8±2.723.6±2.320.3±3.0*20.3±2.0*19.9±2.8* |
组别 | 剂量(g/kg.bw) | 动物数(只) | 体重(克) | 增重(克) | |
试验前 | 试验后 | ||||
空白组低剂量组中剂量组高剂量组 | 00.350.701.05 | 10101010 | 19.99±0.719.93±0.519.98±0.719.95±0.7 | 36.80±0.436.72±0.536.91±0.736.91±0.6 | 16.81±0.416.79±0.416.94±0.416.96±0.4 |
组别 | 剂量(g/kg.bw) | 动物数(只) | 胸腺/体重比值(×10-3) | 脾脏/体重比值(×10-3) |
空白组低剂量组中剂量组高剂量组 | 00.350.701.05 | 10101010 | 2.83±0.102.83±0.102.82±0.092.84±0.09 | 4.46±0.104.47±0.094.47±0.104.47±0.07 |
组别 | 剂量(g/kg.bw) | 注ConA诱导脾淋巴细胞增殖 | DNFB诱导DTH | ||
N | OD差值 | N | 左右耳重量差(mg) | ||
空白组低剂量组中剂量组高剂量组 | 00.350.701.05 | 10101010 | 0.039±0.0030.043±0.003#0.049±0.003*0.056±0.004* | 10101010 | 16.46±0.617.15±0.4#18.27±0.4*19.49±0.4* |
组别 | 剂量(g/kg.bw) | 动物数(只) | 血清溶血素(抗体积数) |
空白组低剂量组中剂量组高剂量组 | 00.350.701.05 | 10101010 | 67.8±14.987.0±13.0*100.8±17.7*115.0±15.0* |
组别 | 剂量(g/kg.bw) | 动物数(只) | 吞噬百分率(%) | 吞噬指数 |
空白组低剂量组中剂量组高剂量组 | 00.350.701.05 | 10101010 | 37.2±2.842.4±2.6*46.1±1.6*48.3±2.7* | 0.42±0.020.47±0.03*0.51±0.02*0.54±0.03* |
组别 | 剂量(g/kg.bw) | 动物数(只) | 吞噬指数 |
空白组低剂量组中剂量组高剂量组 | 00.350.701.05 | 10101010 | 6.753±0.26.067±0.2*5.606±0.2*5.345±0.2* |
组别 | 剂量(g/kg.bw) | 动物数(只) | 溶血空斑数(个/106脾细胞) |
空白组低剂量组中剂量组高剂量组 | 00.350.701.05 | 10101010 | 484±28.7519±11.4*569±26.2*590±30.6* |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03141626 CN1289100C (zh) | 2003-07-14 | 2003-07-14 | 一种具有延缓衰老、免疫调节功能的胶囊及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03141626 CN1289100C (zh) | 2003-07-14 | 2003-07-14 | 一种具有延缓衰老、免疫调节功能的胶囊及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1569082A CN1569082A (zh) | 2005-01-26 |
CN1289100C true CN1289100C (zh) | 2006-12-13 |
Family
ID=34470990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03141626 Expired - Fee Related CN1289100C (zh) | 2003-07-14 | 2003-07-14 | 一种具有延缓衰老、免疫调节功能的胶囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1289100C (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102783638A (zh) * | 2012-07-20 | 2012-11-21 | 章操 | 一种蝙蝠蛾被毛孢菌粉和西洋参混合粉及其制备方法 |
CN105327025A (zh) * | 2015-12-08 | 2016-02-17 | 天津中新药业集团股份有限公司第六中药厂 | 一种具有缓解体力疲劳组合物的制备方法 |
CN110123957A (zh) * | 2018-02-02 | 2019-08-16 | 任雪涛 | 一种激发自身多能性干细胞药食两用组合物 |
-
2003
- 2003-07-14 CN CN 03141626 patent/CN1289100C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1569082A (zh) | 2005-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1301666C (zh) | 一种能增强免疫力的保健食品及其制备方法 | |
DE60035604T2 (de) | Heilmittel | |
CN106819562A (zh) | 提高鹅免疫力的饲料及其制备方法 | |
CN105079089A (zh) | 一种辅助降血糖的葛根苦瓜保健食品制备方法 | |
CN1480522A (zh) | 一种药酒组合物及其制备方法 | |
CN1669478A (zh) | 一种醋蛋粉的制法及含醋蛋粉的组合物及用途 | |
CN109170086A (zh) | 一种具有免疫增强功能的蛋白核小球藻压片糖果及其制备方法 | |
KR101025286B1 (ko) | 다시마의 발효에 의한 다량의 gaba를 함유한 발효산물 및 이를 이용한 기능성 천연 발효조미료와 다시마 발효분말의 제조 방법 | |
CN100444746C (zh) | 一种高寒山区作物精制健康食品及其加工工艺 | |
CN101356975B (zh) | 提高人体免疫及促智健脑的保健食品及其制备方法 | |
CN107223792A (zh) | 肉鸡饲料添加剂及其制备方法和应用 | |
CN1289100C (zh) | 一种具有延缓衰老、免疫调节功能的胶囊及其制备方法 | |
CN1785054A (zh) | 一种具有抗氧化功能的保健食品及其制备工艺 | |
CN1376397A (zh) | 灵芝茶及其制作方法 | |
CN1218745C (zh) | 一种保肝护肝及调节血脂的保健食品及其制备方法 | |
CN1110105A (zh) | “中华麦绿素”及其生产方法 | |
CN1231255C (zh) | 以南瓜为主要原料制备的治疗便秘的胶囊配方及配制方法 | |
CN103933146A (zh) | 一种可调节人体免疫力的花粉制品 | |
CN1063649C (zh) | 一种红参山楂保健酒 | |
CN1186032C (zh) | 动物骨髓提取物与中药提取物配伍制成的保健食品 | |
CN110236047A (zh) | 一种纤体美容的酵素饮品及其制备方法 | |
CN1120015C (zh) | 高效纯天然降血糖剂 | |
CN1259070C (zh) | 对化学性肝损伤有辅助保护作用的保健胶囊及其制备方法 | |
CN108835454A (zh) | 一种蛋鸡饲料添加剂及其制备方法 | |
CN1160095C (zh) | 抗衰老养生膏及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGXI TIANSHIKANG TRADITIONAL CHINESE MEDICINE Free format text: FORMER OWNER: TIANSHIKANG SCIENCE + TECHNOLOGY DEVELOPMENT CO., LTD., JIANGXI PROV. Effective date: 20050624 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050624 Address after: 335000 No. 21, Jianshe Road, Jiangxi, Yingtan Applicant after: Tianshikang Chinese Medicines Co., Ltd., Jiangxi Address before: No. 21, middle station, Yujiang County, Jiangxi Applicant before: Xiangxi Tianshikang Sci-Tech Development Co., Ltd. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Bo Inventor after: Jue Suyun Inventor before: Wu Chaoyang Inventor before: Xu Fahong Inventor before: Huang Jingqiu Inventor before: Yu Xiaohui |
|
COR | Change of bibliographic data | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160620 Address after: 331500 Chengbei Industrial Zone, Yongfeng County, Jiangxi, Ji'an Patentee after: The strong high-tech of Jiangxi Wei Laiying Co., Ltd Address before: 335000 No. 21, Jianshe Road, Jiangxi, Yingtan Patentee before: Tianshikang Chinese Medicines Co., Ltd., Jiangxi |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061213 Termination date: 20160714 |
|
CF01 | Termination of patent right due to non-payment of annual fee |